Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
29
self-reported band not used
Founded
2013
13 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
3
Post IPO equity · Oct 2024 · US$ 3.3M
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
IMUGENE LIMITED
ABN99009179551
Legal entities
Show as table · Imugene Limited: 1 registry entity
| IMUGENE LIMITED | ABN 99009179551 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. ASX: IMU
Specialties
All 16 specialties
- Immuno-oncology
- Cancer Vaccines
- Her-2+ cancers
- Mimotopes
- PD-1
- biotechnology
- immunotherapy
- biotech
- immune system
- cancer experts
- B-cell peptide vaccines
- b-cell
- B-cell vaccine technology
- cancer therapy
- drug development
- immune checkpoint inhibitor monoclonal antibodies
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AU37 Bligh St; Suite 1006, Level 10; Sydney, New South Wales 2000Primary
Grid intelligence Members
Funding
Rounds3
Round typePost IPO equity · secondary transaction
Amount (USD)3,300,000
Stage rank6
Investors named1
Since last round1 yr 3 mo
Funding
Show as table · 3 funding rounds
| Rounds | 3 |
|---|---|
| Axis | 2013 to 2026 |
| Post IPO equity · 3 Oct 2024 | US$ 3.3M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Names are withheld until a consented source exists.
FAQ
Which legal entity operates under Imugene Limited?
One New South Wales entity on the ABR: IMUGENE LIMITED (ABN 99 009 179 551), high confidence.
How many people work at Imugene Limited?
29 counted staff profiles at January 2026. The brand's self-reported band sits above that count and is not published as a headcount.
Where does Imugene Limited have offices?
One address on record, Australia only. Primary: 37 Bligh St, Suite 1006, Level 10, Sydney, New South Wales 2000.
Has Imugene Limited raised funding?
Three rounds. Latest 3 October 2024: post IPO equity, US$3,300,000, investor Precision BioSciences.
What does Imugene Limited list as its specialties?
16 tags on the brand's own list, among them biotechnology and biotech.
Which companies are listed alongside Imugene Limited?
32 profiles list Imugene Limited as a peer — 97th percentile in Biotechnology Research. It lists ten peers of its own. Mesoblast Limited and Immutep Limited list it back.